MARKET

RETA

RETA

Reata Pharmaceut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.18
-0.66
-2.37%
After Hours: 27.18 0 0.00% 16:19 05/18 EDT
OPEN
26.56
PREV CLOSE
27.84
HIGH
28.22
LOW
26.56
VOLUME
494.58K
TURNOVER
3.52M
52 WEEK HIGH
153.41
52 WEEK LOW
20.24
MARKET CAP
991.06M
P/E (TTM)
-3.2545
1D
5D
1M
3M
1Y
5Y
Reata Pharmaceuticals (NASDAQ:RETA) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 3d ago
Reata Pharma surges as Goldman sets a Street high target
Clinical-stage biopharma company, Reata Pharmaceuticals (NASDAQ:RETA) ended a three-day losing streak on Tuesday after Goldman Sachs raised its price target to a Street high of $93 following the Texas-based firm’s
Seekingalpha · 05/10 15:57
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4
Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Zacks · 05/10 14:45
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 11:55
Recap: Reata Pharmaceuticals Q1 Earnings
  Reata Pharmaceuticals (NASDAQ:RETA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 11:30
Reata Pharmaceuticals Q1 EPS $(1.33) Beats $(2.15) Estimate, Sales $914.00K Miss $1.55M Estimate
Reata Pharmaceuticals (NASDAQ:RETA) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(2.15) by 38.14 percent. This is a 14.66 percent decrease over losses of $(1.16) per share
Benzinga · 05/10 10:56
Reata Pharmaceuticals Non-GAAP EPS of -$1.33 beats by $0.63, revenue of $0.91M misses by $0.64M
Reata Pharmaceuticals press release (NASDAQ:RETA): Q1 Non-GAAP EPS of -$1.33 beats by $0.63. Revenue of $0.91M (-3.2% Y/Y) misses by $0.64M. On March 31, 2022, we had cash and cash
Seekingalpha · 05/10 10:44
More
No Data
Learn about the latest financial forecast of RETA. Analyze the recent business situations of Reata Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

44.44%Strong Buy
33.33%Buy
22.22%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RETA stock price target is 59.00 with a high estimate of 93.00 and a low estimate of 35.00.
High93.00
Average59.00
Low35.00
Current 27.18
EPS
Actual
Estimate
-1.88-1.41-0.94-0.47
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 247
Institutional Holdings: 32.69M
% Owned: 89.67%
Shares Outstanding: 36.46M
TypeInstitutionsShares
Increased
49
2.26M
New
33
2.26M
Decreased
48
2.84M
Sold Out
63
1.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/President/Chief Executive Officer/Director
J. Warren Huff
President/Chief Financial Officer/Chief Operating Officer
Manmeet Soni
Executive Vice President
Dawn Bir
Executive Vice President
Colin Meyer
Executive Vice President
Michael Wortley
Chief Accounting Officer/Vice President
Bhaskar Anand
Independent Director
Martin Edwards
Independent Director
William McClellan
Independent Director
R. Kent McGaughy
Independent Director
Jack Nielsen
Independent Director
Christy Oliger
Independent Director
William Rose
Independent Director
Shamim Ruff
No Data
No Data
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.